Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Oral Biologics & Biosimilar Drugs Market CAGR Outlook And Future Development
The oral biologics & biosimilar drugs market size has demonstrated significant expansion over recent years. It is anticipated to grow from $8.6 billion in 2025 to $10.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.0%. This growth observed in the past can be attributed to several factors, including the limited availability of oral biologics, a reliance on injectable biologics, the increasing prevalence of autoimmune and inflammatory diseases, a growing patient demand for cost-effective therapies, and the early approvals of monoclonal antibody drugs.
The oral biologics & biosimilar drugs market is projected to experience substantial expansion over the coming years. Its value is anticipated to reach $17.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast timeframe is primarily driven by the creation of advanced oral biologics, the broadening of the biosimilar pipeline, the growing integration of combination therapies, the proliferation of digital health platforms for patient oversight, and enhanced regulatory backing for biosimilar authorizations. Key developments expected throughout this period encompass the increasing uptake of oral biologics and biosimilar medications, a greater emphasis on managing chronic conditions with biologics, the widening of hospital and retail pharmacy distribution networks, improved patient understanding and acceptance of biosimilars, and the formulation of targeted treatments for autoimmune and inflammatory disorders.
Get A Free Sample Report With In-Depth Market Insights:
Oral Biologics & Biosimilar Drugs Market Growth Factors: What’s Supporting Expansion?
The increasing occurrence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to be a primary catalyst for the oral biologics and biosimilar market. Extended working hours, insufficient physical activity, and unhealthy eating and drinking habits contribute to the widespread nature of chronic conditions, for which biologics are progressively employed as treatment. Biologics function by stimulating the immune system’s reaction against malignant cells, thereby assisting in their removal from the body. For example, a United Nations article in May 2023 indicated that by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is also predicted to reach about 60%. Consequently, the growing incidence of chronic diseases is forecast to boost the need for biologics and biosimilars, thus fostering the expansion of the oral biologics & biosimilar drugs market.
Oral Biologics & Biosimilar Drugs Market Segment Analysis: What Are The Core Market Categories?
The oral biologics & biosimilar drugs market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab
Oral Biologics & Biosimilar Drugs Market Industry Trends: What’s Reshaping Demand?
Leading companies in the oral biologics and biosimilar markets are focusing on innovative products, such as incretin triagonists, to improve patient outcomes, enhance drug efficacy, and offer alternatives to injectable therapies. Incretin triagonists are medications that simultaneously activate three hormone receptors GLP-1, GIP, and glucagon, which play a role in regulating blood sugar, appetite, and metabolism. For instance, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology company, released new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule engineered for administering biologics typically requiring injections, successfully delivered an incretin triagonist targeting GLP-1, GIP, and glucagon receptors, which are key targets in obesity treatment. The RaniPill demonstrated effectiveness comparable to subcutaneous injections, providing a needle-free option with high bioavailability and flexible dosing, thereby establishing it as a promising solution for obesity drug candidates.
Oral Biologics & Biosimilar Drugs Market Top Companies Driving Competitive Growth
Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.
View The Full Oral Biologics & Biosimilar Drugs Market Report:
Oral Biologics & Biosimilar Drugs Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
